ANAB
NASDAQ HealthcareAnaptysBio, Inc. - Common Stock
Biotechnology
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
�� 市场数据
| 价格 | $48.64 |
|---|---|
| 成交量 | 414,328 |
| 市值 | 1.45B |
| 贝塔系数 | 0.450 |
| RSI（14日） | 57.0 |
| 200日均线 | $50.33 |
| 50日均线 | $51.93 |
| 52周最高 | $72.36 |
| 52周最低 | $20.18 |
| Forward P/E | 10.72 |
| Price / Book | 136.63 |
🎯 投资策略评分
ANAB 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (56/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🚀 Moon Shot (28/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ANAB in your text
粘贴任何文章、记录或帖子 — 工具将提取 ANAB 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-10-29.